Synaptogenix, Inc.

Synaptogenix, Inc.

$3.45
-0.06 (-1.71%)
NASDAQ
USD, US
Biotechnology

SNPX Price Chart

Basic
Market Cap$4.53M
Price$3.45
52 Week Range3.269-11.475
Beta1.461
Margins
Gross Profit Margin45.02%
Operating Profit Margin-60035.75%
Net Profit Margin-16670.96%
Valuation (TTM)
P/E Ratio-2.43
Price to Sales Ratio441.34
Price to Book Ratio0.22
PEG Ratio0.00

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Alan J. Tuchman M.D., MBA(FAAN)

Full-Time Employees

5

IPO Date

2020-12-08

Description

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Phone

973 242 0005

Address

1185 Avenue of the Americas, New York, NY, 10036, US

CIK

0001571934